A Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate a Switch to an Oral Weekly Islatravir/Lenacapavir Regimen in People With HIV-1 Who Are Virologically Suppressed on Standard of Care

Woolley, I. (Primary Chief Investigator (PCI))

27/11/24 → 26/11/29

Project: Research

A Phase 3, Randomized, Double-blind, Active-controlled Study to Evaluate a Switch to an Oral Weekly Islatravir/Lenacapavir Regimen in People With HIV-1 Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir (B/F/TAF)

Woolley, I. (Primary Chief Investigator (PCI))

23/11/24 → 22/11/29

Project: Research

A Phase 2 Randomized, Open-label Study to Evaluate the Safety and Efficacy of Broadly Neutralizing Antibodies (bNAbs) GS-5423 and GS-2872 in Combination With the Capsid Inhibitor Lenacapavir as Long-Acting Treatment Dosed Every 6 Months in Virologically Suppressed Adults With HIV-1 Infection

Woolley, I. (Primary Chief Investigator (PCI))

8/08/23 → 7/08/28

Project: Research

PROPHECY: Profiling immune RespOnses in Paediatric and High risk populations to SARS-CoV-2

McMahon, J. (Primary Chief Investigator (PCI)), van Zelm, M. (Chief Investigator (CI)), Khoury, G. (Chief Investigator (CI)), Drummer, H. (Chief Investigator (CI)), Mulley, W. (Chief Investigator (CI)), Holland, A. (Chief Investigator (CI)), Woolley, I. (Chief Investigator (CI)), Ojaimi, S. (Chief Investigator (CI)), Rogers, B. (Chief Investigator (CI)), Hoi, A. (Chief Investigator (CI)), Trauer, J. (Chief Investigator (CI)), Sparrow, M. (Chief Investigator (CI)), Licciardi, P. V. (Chief Investigator (CI)), Giles, E. (Chief Investigator (CI)), Curtis, D. (Chief Investigator (CI)), Crawford, N. (Associate Investigator (AI)), Leech, M. (Associate Investigator (AI)), Westall, G. (Associate Investigator (AI)), O'Hehir, R. (Associate Investigator (AI)), Jones, A. (Associate Investigator (AI)), Morand, E. (Associate Investigator (AI)), Bosco, J. J. (Associate Investigator (AI)) & Turner, S. (Associate Investigator (AI))

Monash University, Alfred Health, Monash Health, Murdoch Children's Research Institute, Burnet Institute (Australia), Spleen Australia, National Association of People with HIV Australia (NAPWHA) Incorporated, Musculoskeletal Australia , Safer Care Victoria (SCV)

1/06/22 → 30/05/26

Project: Research

A Phase 3, Randomized, Clinical Study in HIV-1-Infected Heavily Treatment-Experienced Participants Evaluating the Antiretroviral Activity of Blinded Islatravir (ISL), Doravirine (DOR), and Doravirine/Islatravir (DOR/ISL), Each Compared to Placebo, and the Antiretroviral Activity, Safety, and Tolerability of Open-Label DOR/ISL

Woolley, I. (Primary Chief Investigator (PCI))

9/07/20 → 8/07/25

Project: Research